Tenon Medical Inc Dossier - Source-backed chat

Tenon Medical Inc

TNONNASDAQ

SectorHealth Care

IndustryHealth Care Equipment & Supplies

Beta (adjusted)1.17

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $4.09Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $2.7M

Enterprise Value $1.6M

Shares Outstanding 667K diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Tenon Medical, Inc. is a micro-cap medical device company specializing in sacro-pelvic and sacroiliac (SI) joint fusion systems. The company is demonstrating strong commercial momentum, highlighted by a 90% year-over-year revenue surge in Q1 2026 to $1.4 million and a significant gross margin expansion to 68.5%. This growth is driven by the expanding adoption of its Catamaran platform and the integration of the newly acquired SImmetry+ system. However, these operational achievements are overshadowed by severe liquidity constraints, a persistent net loss ($3.5 million in Q1 2026), and critical regulatory challenges. Tenon has received Nasdaq deficiency notices for failing to maintain both the minimum bid price of $1.00 and the minimum stockholders' equity of $2.5 million. While the upcoming shareholder vote on a reverse stock split and debt conversion authorizations could resolve listing compliance, the company remains a high-risk, speculative play dependent on dilutive capital raises to sustain operations.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$2.25

Mean target$2.63

High · most bullish analyst$3.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Tenon fails to regain compliance with Nasdaq's minimum stockholders' equity or bid price rules, leading to delisting to the OTC markets. Delisting severely restricts access to capital, exacerbating the going concern risk. Commercial adoption of the SImmetry+ and Catamaran platforms stalls due to intense competition from larger medical device peers. The company is forced to execute highly dilutive emergency financing or face restructuring.

Base CaseCentral scenario

The company successfully obtains shareholder approval at the July 23, 2026 annual meeting to execute a reverse stock split and authorize the conversion of its March 2026 senior convertible notes. This allows Tenon to regain compliance with Nasdaq's listing requirements. Commercial adoption of the Catamaran and SImmetry+ platforms continues to scale, supported by the new Tampa training center and Eastern region sales expansion, driving full-year 2026 revenue growth of approximately 60%. Gross margins stabilize in the high 60s. However, cash burn remains high, requiring further dilutive equity rounds, which caps near-term stock price appreciation.

Bull CaseUpside scenario

Successful commercial scaling of the newly integrated SImmetry and SImmetry+ platforms alongside the flagship Catamaran system, driving rapid adoption among new physicians and expanding gross margins to the high 60s as revenue scales.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong top-line growth with Q1 2026 revenue increasing 90% year-over-year to $1.4 million, driven by multi-platform commercial expansion.
Significant gross margin expansion, rising 24 percentage points to 68.5% in Q1 2026 due to improved manufacturing overhead absorption.
Differentiated product portfolio with the Catamaran and SImmetry+ systems offering unique lateral and inferior-posterior surgical approaches.
Robust intellectual property portfolio with 29 issued U.S. patents, 9 international patents, and multiple pending applications extending protection to around 2031.

Key Investment Risks

Going concern warning with a persistent net loss ($3.48 million in Q1 2026) and high operating cash burn ($2.96 million used in Q1 2026).
Nasdaq delisting risk due to non-compliance with the $1.00 minimum bid price (compliance deadline August 24, 2026) and the $2.5 million minimum stockholders' equity requirement.
High risk of shareholder dilution from future equity financings, warrant exercises, and the conversion of outstanding senior convertible promissory notes.
Intense competition in the sacroiliac joint fusion market from larger, well-capitalized medical device companies.

Thesis Invalidation Triggers

Delisting of Tenon's common stock from the Nasdaq Capital Market to the OTC markets.
Failure to secure additional capital or debt restructuring, leading to insolvency or forced asset liquidation.
A material slowdown in quarterly revenue growth or a contraction in gross margins below 60%

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.